A Phase II, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of TAK-385 10, 20, and 40 mg (p.o.) in the Treatment of Endometriosis
收藏DataCite Commons2025-02-10 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009882/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to determine the efficacy and safety of TAK-385, once daily
(QD), for 12 weeks in women with endometriosis.
提供机构：
Vivli
创建时间：
2024-03-14
